{"disease":{"id":"venous-thrombosis","name":"Venous thrombosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"chembl-chembl48361","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"bemiparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"BEMIPARIN","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Factor Xa and thrombin (via antithrombin III enhancement)","drug_class":"Low Molecular Weight Heparin","quality_score":0,"revenue":null,"mechanism":"Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade."},{"drug_id":"fondaparinux","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Prevention of Recurrent Venous Thrombosis Associated with Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"heparin-sodium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Prevention of Recurrent Venous Thrombosis Associated with Malignancy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"acenocoumarol","indication_name":"Venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sintrom","generic_name":"ACENOCOUMAROL","company_name":"","drug_phase":"phase_3","molecular_target":"Vitamin K epoxide reductase complex subunit 1","drug_class":"acenocoumarol","quality_score":null,"revenue":null,"mechanism":"Acenocoumarol works by blocking the enzyme that helps produce clotting factors in the liver."},{"drug_id":"warfarin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"nadroparin-calcium","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fraxiparin","generic_name":"NADROPARIN CALCIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"arixtra","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fraxiparine","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fraxiparine","company_name":"Leiden University Medical Center","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nadroparin","indication_name":"Deep venous thrombosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nadroparin","company_name":"Onze Lieve Vrouwe Gasthuis","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":19,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04969653","title":"The Incidence of Venous Thromboembolism in Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":754745,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947959","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","phase":"","overall_status":"COMPLETED","enrollment_count":665533,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03271450","title":"The DARE Warfarin CER Study","phase":"","overall_status":"UNKNOWN","enrollment_count":416000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947985","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","phase":"","overall_status":"COMPLETED","enrollment_count":208958,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06232551","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":152000,"lead_sponsor_name":"Scott C. Woller, MD","has_results":false},{"nct_id":"NCT02468102","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01947998","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","phase":"","overall_status":"COMPLETED","enrollment_count":50299,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT02943343","title":"The China Pulmonary Thromboembolism Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04972058","title":"Philippine Neurological Association One Database - Stroke","phase":"","overall_status":"COMPLETED","enrollment_count":14800,"lead_sponsor_name":"Philippine Neurological Association","has_results":false},{"nct_id":"NCT02155491","title":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","phase":"","overall_status":"COMPLETED","enrollment_count":10679,"lead_sponsor_name":"Thrombosis Research Institute","has_results":false},{"nct_id":"NCT06581965","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10078,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03367364","title":"Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis","phase":"NA","overall_status":"COMPLETED","enrollment_count":9657,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT03505723","title":"PeriOperative ISchemic Evaluation-3 Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":9535,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT02598609","title":"SEPREVEN: a Stepped-wedge Randomised Controlled Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"Dr Caeymaex Laurence","has_results":false},{"nct_id":"NCT04400877","title":"Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":7795,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT02600260","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":7212,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03773939","title":"Risk Prediction of Venous Thromboembolism in Critically Ill","phase":"","overall_status":"UNKNOWN","enrollment_count":5400,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT03881345","title":"Ongoing Registry of Treatment of Venous Thromboembolism","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Medalp Private Surgery Clinic","has_results":false},{"nct_id":"NCT03281590","title":"Stroke and Cerebrovascular Diseases Registry","phase":"","overall_status":"COMPLETED","enrollment_count":4594,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT02064439","title":"Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3365,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05448248","title":"Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)","phase":"","overall_status":"COMPLETED","enrollment_count":3276,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT04158973","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3200,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03919305","title":"Cerebral Venous Thrombosis Cohort Study in China Mainland","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06258694","title":"Venous Thrombo-Embolism Imaging Database (VTE-ID)","phase":"","overall_status":"COMPLETED","enrollment_count":2208,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT02040103","title":"Pneumatic Compression for Preventing Venous Thromboembolism","phase":"NA","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"King Abdullah International Medical Research Center","has_results":false},{"nct_id":"NCT04256525","title":"Prophylactic Anticoagulation for Catheter-related Thrombosis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1640,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06947707","title":"Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1486,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT04548713","title":"CLiCK in the Critical Care Unit","phase":"NA","overall_status":"COMPLETED","enrollment_count":1449,"lead_sponsor_name":"Fraser Health","has_results":false},{"nct_id":"NCT06195540","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1424,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT04439383","title":"Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1353,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT03327376","title":"Daily Ultrasound-screening for CVC-related Thrombosis","phase":"","overall_status":"COMPLETED","enrollment_count":1262,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05476913","title":"GEKO Venous Thromboembolism Prevention Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Firstkind Ltd","has_results":false},{"nct_id":"NCT06825416","title":"A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1166,"lead_sponsor_name":"Beijing Suncadia Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT05171049","title":"A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1150,"lead_sponsor_name":"Anthos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01828697","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1110,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT02073682","title":"Cancer Venous Thromboembolism (VTE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1046,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT03889457","title":"What Treatment for Patients With Phlebitis or Pulmonary Embolism ?","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT05890924","title":"Intimate Partner Violence as a Risk Factor for Venous Thromboembolism in Women","phase":"","overall_status":"COMPLETED","enrollment_count":997,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT07432529","title":"Design and Rationale of the COLT Study","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":940,"lead_sponsor_name":"Azienda Sanitaria Locale ASL 6, Livorno","has_results":false},{"nct_id":"NCT02301793","title":"Educating Nurses About Venous Thromboembolism (VTE) Prevention","phase":"NA","overall_status":"COMPLETED","enrollment_count":933,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT02744092","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":811,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT05380895","title":"Comparison of Daytime Surgery in Varicose Veins Patients With and Without Superficial Venous Thrombosis","phase":"","overall_status":"UNKNOWN","enrollment_count":699,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02211326","title":"Genotype-guided Warfarin Individualized Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03937583","title":"Screening for Cancer in Patients With Unprovoked VTE","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":650,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT06087952","title":"Leiden Thrombosis Recurrence Risk Prevention","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":608,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT03895502","title":"Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":605,"lead_sponsor_name":"Takeshi Morimoto","has_results":false},{"nct_id":"NCT07372170","title":"Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Infanta Leonor University Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}